In total 65,078 patients were enrolled into 213 clinical trials with 413 treatment arms containing either an artemisinin derivative alone (n=26) or in combination with a partner drug (n=387).
The median sample size per treatment arm was 110 (range 10-1,475), with most of the data derived from comparative drug trials (189, 89%), of which 177 (83%) were randomised trials. The remaining 24 (11%) studies were single-arm studies.
The most frequent treatment regimens reported were: artemether-lumefantrine (AL, in 96 treatment arms), artesunate-mefloquine (AS+MQ, N=75), artesunate-amodiaquine (AS+AQ, N=74), artesunate-sulphadoxine-pyrimethamine (AS+SP, N=43), and dihydroartemisinin-piperaquine (DHA+PIP, N=40). In 26 treatment arms, patients received monotherapy only, including either artesunate (N=17), dihydroartemisinin (N=1), artemisinin (N=3), beta-artemether (N=2) and arterolane (N=3) (as shown in the pie chart).
Where described, treatment was supervised completely in 362 (90%) and partially in 30 (7.5%) of the 402 studies.